Riber reports encouraging first-half 2016
Riber, the molecular beam epitaxy (MBE) specialist, is reporting €7 million in revenues for the first half of 2016, up 23 percent from the first half of 2015. The order book has continued to pick up, with 40 percent growth.
MBE system sales were solid during the first half of 2016. Over the period, Riber billed for two machines, including one production machine, compared with four research machines during the first half of 2015.
Sales of services and accessories (€2.4 million) and cells and sources (€1 million) are up 17 percent overall compared with the first half of 2015. This growth reflects Riber's improved commercial performance on its longstanding markets, combined with the development of its positions in the US following its acquisition of MBE Control Solutions in 2015.
At June 30th, 2016, the breakdown of Riber's revenues was as follows: Asia (56 percent), United States (24 percent) and Europe (20 percent).
At June 30th, 2016, the consolidated order book represented €8.8 million, with five MBE systems (including one production machine) for delivery in 2016 (€6 million; +33 percent), strong growth in orders for services and accessories (€2.1 million; +90 percent), and orders for cells and sources (€0.7 million).
The first half of 2016 confirmed that Riber's order book is picking up again. Against a backdrop of moderate growth for the MBE market, this upturn in commercial business has been driven by the signing of several new contracts and supported by the development of the range of services and accessories offered.
Based on these elements, Riber is able to confirm its 2016 revenue target with growth expected to reach at least 30 percent versus 2015.
